---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-124911"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:05:21.322376+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics presents initial CNTY-101 data supporting multi-dosing strategy at ASH

## Summary
- Single-patient case study at Dose Level 1 (100 million cells) showed six-month durable complete response in high-risk R/R B-cell lymphoma
- CNTY-101 was generally well tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity observed
- Pharmacokinetic data suggested CNTY-101 exposure maintained upon additional cycles without lymphodepletion due to lack of allo-rejection
- Company to host conference call Dec 11 to review additional clinical results from Dose Levels 1 and 2 and plans for systemic lupus erythematosus

## SEC filing metadata
- accession: 0001104659-23-124911
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923124911/0001104659-23-124911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923124911/tm2332547d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-124911
- JSON: https://secwatch.observer/filing/0001104659-23-124911.json
- Plain text: https://secwatch.observer/filing/0001104659-23-124911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.